225 related articles for article (PubMed ID: 31725954)
41. Acute myeloid leukemia with del(X)(p21) and cryptic RUNX1/RUNX1T1 from ins(8;21)(q22;q22q22) revealed by atypical FISH signals.
Jang JH; Yoo EH; Kim HJ; Kim DH; Jung CW; Kim SH
Ann Clin Lab Sci; 2010; 40(1):80-4. PubMed ID: 20124335
[TBL] [Abstract][Full Text] [Related]
42. Complex chromosome 8;21 translocation with associated hyperdiploidy in acute myeloid leukemia (FAB-M2).
Corral Mdel P; Villa O; Alfaro EM; Alonso CN; Baro C; Felice MS; Rossi J; Solé F; Gallego MS
Pediatr Blood Cancer; 2008 Mar; 50(3):651-4. PubMed ID: 17405156
[TBL] [Abstract][Full Text] [Related]
43. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.
Xie W; Wang SA; Yin CC; Xu J; Li S; Bueso-Ramos CE; Medeiros LJ; Tang G
Exp Mol Pathol; 2019 Jun; 108():131-136. PubMed ID: 31004601
[TBL] [Abstract][Full Text] [Related]
44. The immunophenotypic characteristics and flow cytometric scoring system of acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1.
Shang L; Chen X; Liu Y; Cai X; Shi Y; Shi L; Li Y; Song Z; Zheng B; Sun W; Ru K; Mi Y; Wang J; Wang H
Int J Lab Hematol; 2019 Feb; 41(1):23-31. PubMed ID: 30264491
[TBL] [Abstract][Full Text] [Related]
45. Trinh BQ, Ummarino S, Zhang Y, et al. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood. 2021;138(15):1331-1344.
Blood; 2023 May; 141(20):2542. PubMed ID: 37200056
[No Abstract] [Full Text] [Related]
46. A new complex translocation (8;22;21)(q22;q12;q22) in RUNX1/RUNX1T1 acute myeloid leukaemia.
Tay Za K; Shanmugam H; Chin EFM
Malays J Pathol; 2019 Dec; 41(3):333-338. PubMed ID: 31901918
[TBL] [Abstract][Full Text] [Related]
47. CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21).
Iriyama N; Hatta Y; Takeuchi J; Ogawa Y; Ohtake S; Sakura T; Mitani K; Ishida F; Takahashi M; Maeda T; Izumi T; Sakamaki H; Miyawaki S; Honda S; Miyazaki Y; Taki T; Taniwaki M; Naoe T
Leuk Res; 2013 Sep; 37(9):1021-6. PubMed ID: 23810283
[TBL] [Abstract][Full Text] [Related]
48. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
49. Outcome of Core Binding Factor Acute Myeloid Leukemia in Children: A Single-Center Experience.
Mansoor N; Jabbar N; Arshad U; Maqsood S; Habib MA; Raza MR
J Pediatr Hematol Oncol; 2020 Aug; 42(6):e423-e427. PubMed ID: 32496446
[TBL] [Abstract][Full Text] [Related]
50. Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.
Wei H; Liu X; Wang Y; Lin D; Zhou C; Liu B; Qiu S; Gu R; Li Y; Wei S; Gong B; Liu K; Gong X; Liu Y; Zhang G; Fang Q; Zhang J; Jin J; Ma Y; Mi Y; Wang J
Exp Hematol; 2021 Apr; 96():63-72.e3. PubMed ID: 33524443
[TBL] [Abstract][Full Text] [Related]
51. Poor outcome in a pediatric patient with acute myeloid leukemia associated with a variant t(8;21) and trisomy 6.
Kelly MJ; Meloni-Ehrig AM; Manley PE; Altura RA
Cancer Genet Cytogenet; 2009 Feb; 189(1):48-52. PubMed ID: 19167612
[TBL] [Abstract][Full Text] [Related]
52. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
[TBL] [Abstract][Full Text] [Related]
53. [Near-tetraploidy acute myeloid leukemia with RUNX1-RUNX1T1 rearrangement due to cryptic t(8;21)].
Im M; Lee JK; Lee DY; Hong YJ; Hong SI; Kang HJ; Chang YH
Korean J Lab Med; 2009 Dec; 29(6):510-4. PubMed ID: 20046081
[TBL] [Abstract][Full Text] [Related]
54. Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis.
Parihar M; Kumar JA; Sitaram U; Balasubramanian P; Abraham A; Viswabandya A; George B; Mathews V; Srivastava A; Srivastava VM
Leuk Lymphoma; 2012 Jan; 53(1):103-9. PubMed ID: 21745004
[TBL] [Abstract][Full Text] [Related]
55. A complex variant t(8;21) involving chromosome 3 in a child with acute myeloblastic leukemia with eosinophilia (AML M4Eo).
Mathew S; Shurtleff S; Ribeiro RC; Behm FG; Raimondi SC
Leuk Lymphoma; 2003 Jan; 44(1):183-7. PubMed ID: 12691161
[TBL] [Abstract][Full Text] [Related]
56. Dual color FISH on CBF primary acute myeloid leukemia.
Sorour A; Nafea D
Egypt J Immunol; 2008; 15(2):25-31. PubMed ID: 20306685
[TBL] [Abstract][Full Text] [Related]
57. Acute myeloid leukemia patients with variant or unusual translocations involving chromosomes 8 and 21 - A comprehensive cytogenetic profiling of three cases with review of literature.
Akhila Raj TV; Gopinath P; Geetha Raj JA; Narayanan G; Nair SG; Joy Philip DS; Raveendran S; Geetha P; Sreedharan H
J Cancer Res Ther; 2022; 18(3):697-703. PubMed ID: 35900542
[TBL] [Abstract][Full Text] [Related]
58. KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1.
Srinivasan S; Dhamne C; Patkar N; Chatterjee G; Moulik NR; Chichra A; Pallath A; Tembhare P; Shetty D; Subramanian PG; Narula G; Banavali S
Pediatr Blood Cancer; 2024 Feb; 71(2):e30791. PubMed ID: 38014874
[TBL] [Abstract][Full Text] [Related]
59. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
[TBL] [Abstract][Full Text] [Related]
60. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
Hoyos M; Nomdedeu JF; Esteve J; Duarte R; Ribera JM; Llorente A; Escoda L; Bueno J; Tormo M; Gallardo D; de Llano MPQ; Martí JM; Aventín A; Mangues R; Brunet S; Sierra J
Eur J Haematol; 2013 Sep; 91(3):209-218. PubMed ID: 23646898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
